Breast cancer risk reduction therapy: The low-hanging fruit

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 4, 2015, Pages 376-378

  Bevers, Therese B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EXEMESTANE; RALOXIFENE; TAMOXIFEN; ANDROSTANE DERIVATIVE; AROMATASE INHIBITOR; NITRILE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIAZOLE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER RISK; CANCER THERAPY; CLINICAL TRIAL (TOPIC); FOOD AND DRUG ADMINISTRATION; FRAGILITY FRACTURE; FRUIT; GENERAL PRACTITIONER; GYNECOLOGIST; HUMAN; INTERNIST; RISK REDUCTION; BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CLINICAL PRACTICE; FEMALE; HYPERPLASIA; PATHOLOGY;

ANDROSTADIENES; AROMATASE INHIBITORS; BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; FEMALE; HUMANS; HYPERPLASIA; NITRILES; PRACTICE PATTERNS, PHYSICIANS'; RALOXIFENE HYDROCHLORIDE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRIAZOLES;

EID: 84928010633     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0052     Document Type: Article

References (19)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-1388.
2. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
3. Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 2015;16:67-75.
4. Vogel VG: Costantino JP,Wickerham DL, et al. Update of the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res 2010;3:696-706.
5. Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364: 2381-2391.
6. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomized placebo-controlled trial. Lancet 2014;383:1041-1048.
7. Waters EA, McNeel TS, Stevens WM, Freedman AN. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat 2012;134:875-880.
8. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-532.
9. Corbelli J, Borrero S, Bonnema R et al. Use of the Gail model and breast cancer preventive therapy among three primary care specialities. J Womens Health 2014;23:746-752.
10. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-151.
11. Page DL, Kidd TE Jr, Dupont WD, et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 1991;22:1232-1239.
12. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer in white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886.
13. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111-1130.
14. Pankratz VS, Hartmann LC, Degnim AC, et al. Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol 2008;26:5374-5379.
15. Boughey JC, Hartmann LC, Anderson SS, et al. Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol 2010;28:3591-3596.
16. Hartmann LC, Radisky DC, Frost MH, et al. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila) 2014;7:211-217.
17. Coopey SB, Mazzola E, Buckley JM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat 2012;136:627-633.
18. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-1662.
19. Bevers TB, Ward JH, Arun BK, et al. NCCN Clinical Practice Guidelines in Oncology for Breast Cancer Risk Reduction, Version 1.2015; in press.